EGFR 20 ins mutations were more common in patients with normal serum tumor markers (3.83% vs. 1.05%, P = 0.037), and EGFR 21 L858R mutations were more frequent in patients with early stage disease (28.19% vs. 18.09%, P< 0.001). Here, EGFR is linked to neoplasm.